pharmaphorum Daily Newsletter - 28th Jan
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
This Tuesday, Veru's obesity candidate has achieved its objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price nonetheless still fell sharply.
In other news today, regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year, and AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2-ultralow metastatic breast cancer.
Elsewhere, Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company, and Quibim has raised $50 million in first-round financing to support the rollout of its AI biomarkers for use in the analysis of medical imaging.
And in our longer reads today, find out whether VR is the answer to the wait for surgical procedures, and take a look back to key takeaways from the JP Morgan Healthcare Conference as we head further into 2025.
All this and more on pharmaphorum.com.?
News
Veru Inc. 's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.
Quibim has raised $50 million in first-round financing to support the rollout of its AI biomarkers for use in the analysis of medical imaging.
Regulators have started reviews of 荷商葛蘭素史克藥廠 's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.
Enhertu gets much-anticipated new FDA approval in breast cancer that expands its label and makes it an earlier option in the treatment pathway.
Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.
Views & Analysis
With the equivalent of one in ten of the UK’s population having a surgical procedure every year, signs of the great wait slowing are few and far between. Could virtual reality (VR) technology be the answer?
The JP Morgan Healthcare Conference is seen as a barometer for the life sciences industry – and, going into this year’s event, the forecast for the year was particularly grim.
In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s everyday lived experience.
Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs.
Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum. Among the most active voices in this environment are healthcare professionals (HCPs).
领英推荐
Podcasts & Videos
SIFI , an Italian ophthalmology company focused mostly on the European market, doesn’t normally make it out to San Francisco for JP Morgan week. But this year the company is working on launching an exciting new therapy for a rare eye disease and is stretching into the US market for their planned launch. At the conference, editor-in-chief Jonah Comstock met up with SIFI CEO and Chairman Fabrizio Chines to talk about this novel product and some other trends in the eye care space.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Jennifer Schranz M.D. , head of rare diseases at Ipsen , for a conversation focused on rare liver disease primary biliary cholangitis (PBC), which affects nine women for every one man, and the women’s health gap more generally.
At the JP Morgan Healthcare Conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology, Inc. CEO Marianne D. De Backer, MSc, PhD, MBA , who explained a bit more about what a dual-masked T-cell engager is and why they are so promising at mitigating the toxicity of previously attempted TCEs.
At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with 辉瑞 ’s head of predictive analytics, Jonathan Crowther , to discuss the role of AI in life sciences today.
In this pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich , CEO and founder of Quris.AI, about how AI could revolutionise preclinical research and accelerate the development of potentially life-saving drugs, safely.
White Papers & Webinars
In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication planners and medical affairs communications teams can leverage the new impact metrics that matter for journal selection.
In a recent webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’, this forward-looking session explored how imagination and innovation are reshaping the future of healthcare. Available now on demand.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health , have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
An exclusive webinar, sponsored by Trueblue, explores how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge. Available now on demand.
Jordan Lane, co-founder and CSO for Ignota Labs , breaks down the scientific and structural barriers that contribute to high drug failure rates and explores how artificial intelligence (AI) may help to address them. Read this and more in Deep Dive: AI 2024.